FDA Approves RVMD Rasonque, First RAS Inhibitor for Pancreatic Cancer

The FDA approved Revolution Medicines’ Rasonque (daraxonrasib) on August 26, clearing the first-in-class targeted therapy that blocks RAS in its active “on” state, the driver behind most pancreatic cancers. The approval covers adults with metastatic pancreatic adenocarcinoma who have received at least one prior line of systemic therapy or are not candidates for multiagent systemic therapy.

Rasonque is a once-daily oral tablet that hits multiple RAS mutations, not just the KRAS G12C subset addressed by Amgen’s Lumakras. In the registrational RASolute 302 trial, 500 adults with previously treated metastatic disease who received Rasonque lived a median 13.2 months versus 6.7 months for those on standard chemotherapy. The drug nearly doubled overall survival in a disease where the current standard of care buys patients under seven months.

The approval landed 6.5 months before the user fee deadline under the Commissioner’s National Priority Voucher (CNPV) pilot program, roughly five weeks after the FDA accepted the application in late July. Rasonque also carries Breakthrough Therapy, Orphan Drug, and Priority Review designations.

“Today’s approval provides a critical new option for patients facing an extraordinarily difficult and historically hard-to-treat cancer,” said Acting FDA Commissioner Kyle Diamantas. Angelo de Claro, director of the FDA’s Oncology Center of Excellence, described the results as “unprecedented in an area of high unmet need.”

Pancreatic adenocarcinoma accounts for 90% to 95% of the roughly 67,000 pancreatic cancer cases diagnosed in the US each year, according to the National Cancer Institute. It makes up only about 3.2% of cancer diagnoses yet drives a disproportionately high share of cancer deaths because it is usually caught late and has had few effective options. The most common side effects of Rasonque include rash, diarrhea, stomatitis, nausea, fatigue, vomiting, abdominal pain, edema, decreased appetite, and hemorrhage.

The stock barely moved on the news. RVMD closed at $215.44, up 1.9% from its $211.38 prior close, after running from about $189 in late July as approval became priced in. That matches our earlier read that second-line approval was the base case. The catalysts that move the stock next are first-line pancreatic cancer (RASolute 303), NSCLC (RASolve 301), and the RAS(ON) pipeline tied into the BeOne Medicines collaboration.

What to watch next: launch pricing and the first sales prints, plus readouts from the first-line and NSCLC trials that determine whether Rasonque becomes a franchise or stays a single-indication drug.

Source: FDA press release, August 26, 2026